Get the Stockscreener App
2.1945
6.79%
0.1395
Sab Biotherapeutics Inc stock is traded at $2.1945, with a volume of 72,924.
It is up +6.79% in the last 24 hours and down -15.92% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$2.055
Open:
$2.09
24h Volume:
72,924
Relative Volume:
0.05
Market Cap:
$22.85M
Revenue:
-
Net Income/Loss:
$-45.57M
P/E Ratio:
-0.3483
EPS:
-6.3
Net Cash Flow:
$-38.56M
1W Performance:
-1.15%
1M Performance:
-15.92%
6M Performance:
+20.58%
1Y Performance:
-18.72%
1-Day Range:
$2.07
$2.2001
1-Week Range:
$1.965
$2.24
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.1945 | 20.25M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Stock (SABS) Latest News
How to integrate SAB Biotherapeutics Inc. Equity Warrant into portfolio analysis toolsJuly 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Using economic indicators to assess SAB Biotherapeutics Inc. Equity Warrant potentialExit Point & Weekly High Return Opportunities - Newser
Chart based exit strategy for SAB Biotherapeutics Inc.2025 Winners & Losers & Risk Managed Investment Strategies - Newser
How sentiment analysis helps forecast SAB Biotherapeutics Inc.Portfolio Gains Summary & Daily Chart Pattern Signals - Newser
What the charts say about SAB Biotherapeutics Inc. todayGlobal Markets & Community Shared Stock Ideas - Newser
Price momentum metrics for SAB Biotherapeutics Inc. explainedBond Market & Capital Efficiency Focused Ideas - Newser
Heatmap Data Shows High Activity in SAB Biotherapeutics Inc. Sector2025 Institutional Moves & Consistent Return Strategy Ideas - beatles.ru
What indicators show strength in SAB Biotherapeutics Inc.Trend Reversal & Daily Technical Forecast Reports - Newser
Is now a turning point for SAB Biotherapeutics Inc.2025 Price Momentum & High Accuracy Swing Trade Signals - Newser
Using portfolio simulators with SAB Biotherapeutics Inc. included2025 Market Outlook & Proven Capital Preservation Tips - Newser
Using economic indicators to assess SAB Biotherapeutics Inc. potentialProfit Target & Daily Oversold Stock Bounce Ideas - Newser
SAB Biotherapeutics Inc. Equity Warrant stock chart pattern explainedJuly 2025 EndofMonth & Precise Swing Trade Entry Alerts - Newser
SAB Biotherapeutics Inc. stock momentum explainedEarnings Recap Summary & Consistent Income Trade Ideas - Newser
Can SAB Biotherapeutics Inc. hit a new high this monthMarket Risk Summary & Safe Entry Trade Signal Reports - Newser
Predicting SAB Biotherapeutics Inc. trend using moving averagesMarket Growth Review & Free Fast Gain Swing Trade Alerts - Newser
What MACD signals say about SAB Biotherapeutics Inc.Trade Entry Report & Weekly Momentum Picks - Newser
Automated trading signals detected on SAB Biotherapeutics Inc. Equity WarrantMarket Risk Analysis & Short-Term High Return Ideas - Newser
Advanced analytics toolkit walkthrough for SAB Biotherapeutics Inc. Equity Warrant2025 Major Catalysts & Accurate Technical Buy Alerts - Newser
Multi asset correlation models including SAB Biotherapeutics Inc.Quarterly Growth Report & High Yield Stock Recommendations - Newser
Technical analysis overview for SAB Biotherapeutics Inc. stock2025 Market Overview & Weekly High Return Opportunities - Newser
What recovery options are there for SAB Biotherapeutics Inc. Equity WarrantOil Prices & Low Drawdown Investment Strategies - Newser
Will SAB Biotherapeutics Inc. Equity Warrant continue its uptrendEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
Real time breakdown of SAB Biotherapeutics Inc. stock performance2025 Big Picture & Reliable Intraday Trade Plans - Newser
Risk adjusted return profile for SAB Biotherapeutics Inc. Equity Warrant analyzedGap Down & Real-Time Stock Entry Alerts - Newser
Published on: 2025-08-19 04:33:03 - beatles.ru
Key metrics from SAB Biotherapeutics Inc.’s quarterly dataJuly 2025 Patterns & Verified Technical Signals - Newser
Will SAB Biotherapeutics Inc. stock benefit from interest rate changes2025 Top Decliners & Weekly Return Optimization Plans - Newser
Analyzing SAB Biotherapeutics Inc. Equity Warrant with risk reward ratio chartsCEO Change & Daily Entry Point Alerts - Newser
Measuring SAB Biotherapeutics Inc.’s beta against major indicesMarket Performance Report & Long-Term Capital Growth Strategies - Newser
Identifying reversal signals in SAB Biotherapeutics Inc.Weekly Gains Report & Safe Capital Growth Trade Ideas - Newser
Applying Elliott Wave Theory to SAB Biotherapeutics Inc. Equity WarrantInflation Watch & Weekly Stock Breakout Alerts - Newser
Analyzing SAB Biotherapeutics Inc. with multi timeframe chartsJuly 2025 Analyst Calls & Proven Capital Preservation Methods - Newser
What is SAB Biotherapeutics Inc. Equity Warrant’s TAM (Total Addressable Market)Quarterly Performance Summary & Long-Term Safe Investment Ideas - 선데이타임즈
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):